The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.

Disclosed are compounds having the formula:

##STR00001## wherein X, Y, Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, R.sup.5, R.sup.A, m, A. L, and B are as defined herein, and methods of making and using the same.

The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Antibodies to tropomysin receptor kinase (TrkA), compositions including such antibodies, and methods of using such antibodies for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.

Antibodies to tropomysin receptor kinase (TrkA), compositions including such antibodies, and methods of using such antibodies for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.

The present invention provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof and (ii) a penetration enhancer, and optionally including tannic acid, or an analogue or derivative thereof. The present invention also provides a topical formulation including (i) comfrey or a comfrey-derived compound, or an analogue or derivative thereof, and (ii) tannic acid, or an analogue or derivative thereof, optionally including a penetration enhancer. Also provided are kits and methods of prophylactic or therapeutic treatment of inflammatory and/or degenerative conditions using the combination of active ingredients as herein described.

Methods for transmammary administration of an analgesic to offspring swine are disclosed, which are useful for mitigating, inhibiting, and/or reducing pain in offspring swine prior to undergoing processing procedures that would cause or result in pain. The methods generally comprise administering, via injection, a cyclooxygenase-2 inhibitor class analgesic directly to a lactating female swine. The analgesic is passed indirectly to the offspring swine through the milk of the treated lactating female swine and has beneficial effects, including increases in weight gain, performance, and decreases in pain. A single dosage form injected into the lactating female is suitable for achieving indirect therapeutically effective levels of the cyclooxygenase-2 inhibitor class analgesic in the milk for the offspring.

Methods for transmammary administration of an analgesic to offspring swine are disclosed, which are useful for mitigating, inhibiting, and/or reducing pain in offspring swine prior to undergoing processing procedures that would cause or result in pain. The methods generally comprise administering, via injection, a cyclooxygenase-2 inhibitor class analgesic directly to a lactating female swine. The analgesic is passed indirectly to the offspring swine through the milk of the treated lactating female swine and has beneficial effects, including increases in weight gain, performance, and decreases in pain. A single dosage form injected into the lactating female is suitable for achieving indirect therapeutically effective levels of the cyclooxygenase-2 inhibitor class analgesic in the milk for the offspring.

The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C.sub.15-C.sub.25) hydroxyalkanoic acid), an antioxidant, and water.

The invention provides stable, aqueous capsaicin injectable formulations, a unit dose containing such injectable formulations, medical kits, and methods for using such injectable formulations and unit doses to treat patients suffering from pain, such as osteoarthritic knee pain. The stable, aqueous capsaicin injectable formulations may contain, for example, capsaicin, a solubilizing agent (e.g., a polyethylene glycol ester of a (C.sub.15-C.sub.25) hydroxyalkanoic acid), an antioxidant, and water.